Earnings Releases·Nov 12, 2026, 4:16 PM ET

CytoSorbents — Third Quarter 2026 Earnings Summary

Q3 2026 revenue rose 3% to $9.7 million year-over-year, while gross margin expanded to 75%; operating loss narrowed 59% to $1.2 million and net loss improved 42% to $1.8 million, driven by an 11% reduction in operating expenses.
The company achieved its target of operating cash flow breakeven in the second half of 2026, generating approximately $43,000 in positive operating cash flow before restructuring payments, though total cash reserves declined to $5.7 million.
Strategic outlook includes a new FDA De Novo submission for DrugSorb-ATR expected in early 2027, expansion of the German sales team, and evaluation of non-dilutive funding or partnerships for HemoDefend-BGA.
Significant balance sheet shifts include a $1.9 million non-cash foreign currency loss impacting nine-month net results, a stockholders' equity deficit of $2.3 million, and current maturities of long-term debt rising to $17.5 million.
Sales performance showed a 16% year-over-year increase in distributor and strategic partner channels, offset by a 20% decline in Germany due to commercial restructuring, while inventory levels decreased to $3.2 million.